drugset / Trial / NCT00277069

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

NCT00277069

Phase 1/2 Completed 33 enrolled University of New Mexico
NaSingle-groupOpen-labelTreatment

Summary

1\. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.

Timeline

Start
2000-05
Primary completion
2005-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1500 mg/m2 Oral
Subject Carboplatin Small molecule 300 mg/m2 Intravenous
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous

Indications